search
Back to results

Validation Study of a Peri-intervention Diabetes Management Algorithm (DIAPI) for Endoscopy Procedures

Primary Purpose

Diabetes Mellitus

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Peri-intervention Diabetes Management Algorithm (DIAPI)
Usual Care
Sponsored by
Centre hospitalier de l'Université de Montréal (CHUM)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus focused on measuring Peri-procedural, Endoscopy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Living with diabetes mellitus for at least 6 months Receiving pharmacological treatment for diabetes mellitus Awaiting an endoscopy intervention scheduled in 2 weeks or more in order to have time to prepare for the study participation Exclusion Criteria: Undergoing an urgent endoscopy intervention Being pregnant Currently treated with an insulin pump or the insulin Entuzity

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Usual Care

    DIAPI

    Arm Description

    Patients will receive usual care for their diabetes during their peri-procedural period.

    Patients will receive the care for their diabetes recommended by the DIAPI algorithm during their peri-procedural period.

    Outcomes

    Primary Outcome Measures

    Concordance rate of duplicate prescriptions generated by DIAPI when two different healthcare workers collect data for the same patient. (Part 1 of study)
    Concordance and discordance are dichotomic concepts. To classify this binary issue, the investigators use a home-made ''Difference Score''. The components of this score have been established to ensure patient safety by minimizing the risk of hypoglycemia, hyperglycemia, and diabetic ketoacidosis. Concordance = difference score of ≤ 25.0 %. Discordant= difference score of > 25.0 %.
    proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)
    The glycaemia will be measured at least every hour for the duration of the stay in the endoscopy unit.

    Secondary Outcome Measures

    Proportion of DIAPI orders for which the endocrinologist disagrees with at least one of its recommendations. (Part 1 of study)
    Proportion of participants for whom an endocrinology consultation was recommended by DIAPI. (Part 1 of study)
    Healthcare workers' satisfaction level with the use of DIAPI, assessed by a questionnaire. (Part 1 of study)
    Proportion of participants who followed DIAPI recommendations. (Part 2 of study)
    • Proportion of canceled endoscopies due to dysglycemia, ketoacidosis or for reasons related to diabetes management. (Part 2 of study)
    Proportion of participants hospitalized for a diabetes-related condition. (Part 2 of study)
    Proportion of participants who experienced: episode of hypoglycemia <3 and < 4 mmol/L, episode of hyperglycemia >10, > 15 and >20 mmol/L, episode of ketoacidosis. (Part 2 of study)
    These episodes will be reported by time frame: the day before, the same day and the day after the intervention.

    Full Information

    First Posted
    April 25, 2023
    Last Updated
    August 7, 2023
    Sponsor
    Centre hospitalier de l'Université de Montréal (CHUM)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05849714
    Brief Title
    Validation Study of a Peri-intervention Diabetes Management Algorithm (DIAPI) for Endoscopy Procedures
    Official Title
    Validation Study of a Peri-intervention Diabetes Management Algorithm (DIAPI) for Endoscopy Procedures
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    January 31, 2024 (Anticipated)
    Study Completion Date
    January 31, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Centre hospitalier de l'Université de Montréal (CHUM)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The peri-endoscopy management of diabetes mellitus creates significant challenges for both patients and healthcare professionals. These procedures require fasting and in certain situations, such as prior to a colonoscopy, the diet must be modified the day before the intervention and patients need to take a laxative. These factors put patients at high risk for hyperglycemia and hypoglycemia. Inadequate diabetes control or the continuation of certain medications during this period can be dangerous for the patient and lead to the cancellation of the procedure. DIAPI is a web application designed to generate orders for optimal and personalized treatment based on each patient's antidiabetic treatment, their glycemic control, their risk of hypoglycemia, and the intervention-related variables. DIAPI's algorithm is established on current evidence-based data when available, and experts' opinions. Information generated by DIAPI: For the patient: Clear instructions regarding their diabetes medication management for the days preceding and the day of the endoscopy. For the health care team: Clear instructions regarding patient's diabetes medication management for the days preceding and the day of the endoscopy; Individualized hyperglycemia protocol; Hypoglycemia protocol; Guidelines if SGLT2 inhibitors have not been discontinued pre-intervention; Suggestion on whether an Endocrinology consultation is needed. DIAPI aims to simplify the complex task of peri-intervention diabetes management while ensuring patient safety. It is a cost-effective solution that can lead to a reduction of unnecessary Endocrinology consultations, a decrease in nurses' workload, a lessening of the risk of errors and a diminution of endoscopy cancellation. The validation study is divided into two main phases. Phase 1 - Concordance. The investigators will assess the reproducibility of DIAPI orders when two different healthcare workers (an endocrinologist and a nurse) collect data for the same patient. The investigators hypothesize that DIAPI orders are concordant in 80%. Patients in this phase will be subjected to the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's. This group will be the control arm for the non-inferiority study (Phase 2). Phase 2 - Non-inferiority study. The investigators hypothesize that DIAPI's orders are not inferior to the recommendations issued by the treating-physician in terms of efficacy and security. Patients in this phase will be subjected DIAPI's orders. This group will be the intervention arm for the non-inferiority study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus
    Keywords
    Peri-procedural, Endoscopy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Sequential Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    160 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Usual Care
    Arm Type
    Active Comparator
    Arm Description
    Patients will receive usual care for their diabetes during their peri-procedural period.
    Arm Title
    DIAPI
    Arm Type
    Experimental
    Arm Description
    Patients will receive the care for their diabetes recommended by the DIAPI algorithm during their peri-procedural period.
    Intervention Type
    Other
    Intervention Name(s)
    Peri-intervention Diabetes Management Algorithm (DIAPI)
    Intervention Description
    Patients and healthcare workers will apply DIAPI's orders.
    Intervention Type
    Other
    Intervention Name(s)
    Usual Care
    Intervention Description
    Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
    Primary Outcome Measure Information:
    Title
    Concordance rate of duplicate prescriptions generated by DIAPI when two different healthcare workers collect data for the same patient. (Part 1 of study)
    Description
    Concordance and discordance are dichotomic concepts. To classify this binary issue, the investigators use a home-made ''Difference Score''. The components of this score have been established to ensure patient safety by minimizing the risk of hypoglycemia, hyperglycemia, and diabetic ketoacidosis. Concordance = difference score of ≤ 25.0 %. Discordant= difference score of > 25.0 %.
    Time Frame
    1 week
    Title
    proportion of patients with glycaemia level within target from arrival to departure from the endoscopy unit, i.e. between 4 - 10 mmol/L. (Part 2 of study)
    Description
    The glycaemia will be measured at least every hour for the duration of the stay in the endoscopy unit.
    Time Frame
    1 day
    Secondary Outcome Measure Information:
    Title
    Proportion of DIAPI orders for which the endocrinologist disagrees with at least one of its recommendations. (Part 1 of study)
    Time Frame
    1 week
    Title
    Proportion of participants for whom an endocrinology consultation was recommended by DIAPI. (Part 1 of study)
    Time Frame
    1 week
    Title
    Healthcare workers' satisfaction level with the use of DIAPI, assessed by a questionnaire. (Part 1 of study)
    Time Frame
    1 week
    Title
    Proportion of participants who followed DIAPI recommendations. (Part 2 of study)
    Time Frame
    1 week
    Title
    • Proportion of canceled endoscopies due to dysglycemia, ketoacidosis or for reasons related to diabetes management. (Part 2 of study)
    Time Frame
    1 week
    Title
    Proportion of participants hospitalized for a diabetes-related condition. (Part 2 of study)
    Time Frame
    1 month
    Title
    Proportion of participants who experienced: episode of hypoglycemia <3 and < 4 mmol/L, episode of hyperglycemia >10, > 15 and >20 mmol/L, episode of ketoacidosis. (Part 2 of study)
    Description
    These episodes will be reported by time frame: the day before, the same day and the day after the intervention.
    Time Frame
    1 week

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Living with diabetes mellitus for at least 6 months Receiving pharmacological treatment for diabetes mellitus Awaiting an endoscopy intervention scheduled in 2 weeks or more in order to have time to prepare for the study participation Exclusion Criteria: Undergoing an urgent endoscopy intervention Being pregnant Currently treated with an insulin pump or the insulin Entuzity
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Lillian Ruiheng Chen, MD
    Phone
    15148908000
    Ext
    28252
    Email
    lillian.ruiheng.chen.med@ssss.gouv.qc.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jean-Marie Boutin, MD, PhD
    Organizational Affiliation
    Université de Montréal
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Validation Study of a Peri-intervention Diabetes Management Algorithm (DIAPI) for Endoscopy Procedures

    We'll reach out to this number within 24 hrs